UB Paderborn / Katalog / Suche / in CDI

1 – 11 von 11

Sortiert nach

In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations

International journal of pharmaceutics, 2012-05, Vol.428 (1-2), p.8-17

2012

Link zum Volltext

Verfügbarkeit prüfen

Improved Ziprasidone Formulations with Enhanced Bioavailability in the Fasted State and a Reduced Food Effect

Pharmaceutical research, 2011-12, Vol.28 (12), p.3159-3170

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone

Journal of controlled release, 2015-09, Vol.213, p.10-17

2015

Link zum Volltext

Verfügbarkeit prüfen

Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development

Biotechnology and bioengineering, 2010-02, Vol.105 (2), p.409-420

2010

Link zum Volltext

Verfügbarkeit prüfen

Model predicting impact of complexation with cyclodextrins on oral absorption

Biotechnology and bioengineering, 2013-09, Vol.110 (9), p.2536-2547

2013

Link zum Volltext

Verfügbarkeit prüfen

Assessment of the feasibility of oral controlled release in an exploratory development setting

Drug discovery today, 2005-09, Vol.10 (17), p.1159-1166

Thombre, Avinash G.

2005

Link zum Volltext

Verfügbarkeit prüfen

Drug Salts and Solubilization: Modeling the Influence of Cyclodextrins on Oral Absorption

Annals of biomedical engineering, 2011, Vol.39 (1), p.455-468

2011

Link zum Volltext

Verfügbarkeit prüfen

Solid Nanocrystalline Dispersions of Ziprasidone with Enhanced Bioavailability in the Fasted State

Molecular pharmaceutics, 2012-12, Vol.9 (12), p.3526-3534

2012

Link zum Volltext

Verfügbarkeit prüfen

Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation

Biotechnology and bioengineering, 2010-02, Vol.105 (2), p.421-430

2010

Link zum Volltext

Verfügbarkeit prüfen

Formulation design and pharmaceutical development of a novel controlled release form of azithromycin for single-dose therapy

Drug development and industrial pharmacy, 2009-12, Vol.35 (12), p.1522-1529

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 11 von 11

Suche als RSS-Feed

Aktive Filter

ThemaSolubility

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(11)

Sprache

Englisch
(11)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations

Improved Ziprasidone Formulations with Enhanced Bioavailability in the Fasted State and a Reduced Food Effect

Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone

Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development

Model predicting impact of complexation with cyclodextrins on oral absorption

Assessment of the feasibility of oral controlled release in an exploratory development setting

Drug Salts and Solubilization: Modeling the Influence of Cyclodextrins on Oral Absorption

Solid Nanocrystalline Dispersions of Ziprasidone with Enhanced Bioavailability in the Fasted State

Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm

Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation

Formulation design and pharmaceutical development of a novel controlled release form of azithromycin for single-dose therapy

Aktive Filter

Suchergebnisse filtern